When EMA and FDA decisions conflict: differences in patients or in regulation?

@article{Wolfe2013WhenEA,
  title={When EMA and FDA decisions conflict: differences in patients or in regulation?},
  author={S. Wolfe},
  journal={BMJ : British Medical Journal},
  year={2013},
  volume={347}
}
  • S. Wolfe
  • Published 2013
  • Medicine
  • BMJ : British Medical Journal
In his new regular column Sid Wolfe asks why the two regulatory bodies have arrived at different decisions on the same diet drugs 
Illicit Internet availability of drugs subject to recall and patient safety consequences
Evolution of pharmacological obesity treatments: focus on adverse side‐effect profiles
Horizons in the Pharmacotherapy of Obesity
Medications for the treatment of obesity in adolescents
Current Perspectives on Long-term Obesity Pharmacotherapy.
  • S. Wharton
  • Medicine
  • Canadian journal of diabetes
  • 2016
Capsaicinoids : a potential role for weight management
Pharmacotherapy for weight loss
...
1
2
...

References

SHOWING 1-10 OF 12 REFERENCES
Withdrawal of sibutramine in Europe
European regulatory body recommends suspension of rosiglitazone
  • D. Cohen
  • Medicine
  • BMJ : British Medical Journal
  • 2010
Elevated heart rate: a "new" cardiovascular risk factor?
  • P. Palatini
  • Medicine
  • Progress in cardiovascular diseases
  • 2009
FDA approves Belviq to treat some overweight or obese adults.
  • Medicine
  • Home healthcare nurse
  • 2012
22529: lorcaserin hydrochloride tablets, 10 mg [FDA briefing document for 10 May 2012 advisory committee meeting
    Advisory Committee meeting for phentermine/topiramate (Qnexa) [briefing memo
      Application number 022529Orig1s000: approval letter
        Clinical briefing document: Endocrinologic and Metabolic Drugs Advisory Committee meeting
          FDA approves weight-management drug Qsymia
            Medications target long-term weight control
              ...
              1
              2
              ...